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Abstract Intimal hyperplasia is one of the prominent
failure mechanisms for arteriovenous fistulas and arterio-
venous access grafts. Human tissue-engineered vascular
grafts (TEVGs) were implanted as arteriovenous grafts in a
novel baboon model. Ultrasound was used to monitor flow
rates and vascular diameters throughout the study. Intimal
hyperplasia in the outflow vein of TEVGs was assessed at
the anastomosis and at juxta-anastomotic regions via
histological analysis, and was compared to intimal hyper-
plasia with polytetrafluoroethylene (PTFE) grafts in the
baboon model and in literature reports from other animal
models. Less venous intimal hyperplasia was observed in
histological sections with arteriovenous TEVGs than with
arteriovenous PTFE grafts. TEVGs were associated with a
mild, noninflammatory intimal hyperplasia. The extent of
intimal tissue that formed with TEVG placement correlated
with the rate of blood flow through tissue engineered
vascular grafts at 2 weeks postimplant. Outflow vein
dilatation was observed with increased flow rate. Both
mid-graft flow rates and outflow vein diameters reached a
plateau by week 4, which suggested that venous remodeling
and intimal hyperplasia largely occurred within the first
4 weeks of implant in the baboon model. Given their
compliant and noninflammatory nature, TEVGs appear
resistant to triggers for venous intimal hyperplasia that are
common for PTFE arteriovenous grafts, including (1)
abundant proinflammatory macrophage populations that
are associated with PTFE grafts and (2) compliance
mismatch between PTFE grafts and the outflow vein. Our
findings suggest that arteriovenous TEVGs develop only a
mild form of venous intimal hyperplasia, which results
from the typical hemodynamic changes that are associated
with arteriovenous settings.
Keywords Tissue-engineered vascular graft.Intimal
hyperplasia.Arteriovenous graft.Remodeling.Blood flow
rate.Noninflammatory
Introduction
There are more than 347,000 patients on chronic hemodi-
alysis [1]. Each year, more than 100,000 new end stage
renal disease patients begin therapy on hemodialysis [1].
Native arteriovenous fistulas have recently been the first
choice for access, but even with the best surgical care,
fistula prevalence is only 47% in the USA [2]. The
remainder of access is dependent on arteriovenous grafts
or catheters, with a preference for grafts when possible [3].
Currently, most arteriovenous grafts that are placed for
hemodialysis access are comprised of synthetic polytetra-
fluoroethylene (PTFE). Synthetic arteriovenous grafts suffer
from significant drawbacks, which include a high rate of
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DOI 10.1007/s12265-011-9306-yinfection (9% per annum) and a propensity for occlusion
due to thrombosis and intimal hyperplasia (40–60% in the
first year), with a median patency of only 10 months [4–7].
PTFE grafts require frequent interventions to maintain
patency throughout their lifetime, which necessitates costly
surgical intervention, increased overall healthcare costs, and
increased patient morbidity [8, 9].
By some reports, up to 85% of PTFE graft failures
result from intimal hyperplasia at either the venous
anastomosis or outflow vein [10]. Intimal hyperplasia is
typically characterized by intimal thickening of the vein,
which diminishes the vein lumen, decreases blood flow
rate, may lead to postcannulation bleeding due to intra-
graft pressurization, and eventually leads to thrombosis
and occlusion [11] .T h ei n t i m ai sd e f i n e da st h ei n n e r m o s t
layer of an artery or vein, on the luminal side of the
internal elastic lamina. In a healthy vein, the intima is one
cell layer thick and comprised solely of endothelial cells.
With intimal hyperplasia, cells may migrate into the intima
from the medial and adventitial layers of the vein and from
the circulation [10, 12, 13]. Once they migrate into the
intima, these cells express markers for myofibroblast and
smooth muscle cell phenotypes. The cells proliferate and
deposit extracellular matrix proteins [10, 14]. The formation
of new tissue in the intima can compromise blood flow.
Intimal hyperplasia is thought to be triggered by the high
wall shear stresses created by A Vg r a f t s[ 15], and compliance
mismatch between PTFE and the native vein [11]. Intimal
hyperplasia also has been identified in regions with turbulent
flow, flow separation, low shear stress, and oscillatory shear
[15]. In addition, PTFE’s synthetic composition commonly
leads to inflammation at the graft placement site following
implant, which promotes intimal hyperplasia formation [10].
Development of tissue-engineered vascular grafts may
provide a new opportunity for hemodialysis patients. If
designed correctly, a tissue-engineered graft has the
potential to reduce incidence of failure mechanisms
associated with PTFE grafts. We have recently described a
new human tissue-engineered vascular graft (TEVG) with
compliance between that of human vein and human artery
[16], which obviates concern about compliance mismatch.
Furthermore, our TEVGs are made of extracellular matrix
proteins, which make them highly biocompatible and
resistant to inflammation [16]. These TEVGs are acellular,
which allows them to be stored in simple refrigeration for
up to 1 year, thereby making them readily available to
patients at the time of need [16]. We demonstrated excellent
function of these TEVGs in multiple vascular settings.
TEVGs placed as arteriovenous grafts in a baboon model
for 1–6 months demonstrated a patency rate of 88%,
without incidence of graft infection [16].
In this study, we evaluate intimal hyperplasia formation
associated with arteriovenous placement of TEVGs. We
also investigate the impact of flow rate and outflow vein
remodeling on intimal hyperplasia formation.
Materials and Methods
Formation of TEVGs
Human TEVGs were made as described previously [16].
Briefly, human aortic smooth muscle cells were isolated
from donor aortas that were consented for research use.
Cells were seeded onto tubular polyglycolic acid felt
scaffolds (6 mm inner diameter) and strained cyclically
(2.5% at 2.75 Hz) [17] in a bioreactor to produce grafts.
The medium for growth of human TEVGs was high
glucose Dulbecco’s modified Eagle’s medium with 20%
serum, 0.13 U/ml insulin, 10 ng/ml basic fibroblast growth
factor, 0.5 ng/ml epidermal growth factor, 10,000 U/ml
penicillin G, 3 ng/ml copper sulfate, 50 ng/ml L-proline,
40 ng/ml L-alanine, and 50 ng/ml glycine, and was changed
thrice weekly. L-Ascorbic acid was added thrice weekly to
TEVG cultures.
After 10 weeks of culture, TEVGs were decellularized as
described previously [18] in phosphate-buffered saline with
0.12 M sodium hydroxide, 1 M sodium chloride, and
25 mM EDTA, containing either 8 mM CHAPS or 1.8 mM
sodium dodecyl sulfate. TEVGs were exposed to each
detergent solution for up to 6 h at room temperature and
were then washed with phosphate-buffered saline. All
TEVGsweredecellularizedpriorimplantation.Decellularized
TEVGs were stored at 4°C in phosphate buffered saline
without calcium or magnesium.
Animal Use
All procedures were approved by Duke University’s
Animal Care and Use Committee. Baboons received
humane care according to the “Guide for the Care and
Use of Laboratory Animals” [19]. All surgical procedures
were performed in sterile fashion under general anesthesia.
After each surgery, graft patency was confirmed, wounds
were closed, and animals were recovered. Baboons were
anticoagulated with heparin at implant (100 U/kg given
intravenously followed by 1,000 U/h for the duration of the
procedure) and received aspirin (10 mg/kg) daily preoper-
atively until the end of the study.
An old world primate model was chosen to provide
phylogenetic similarity to humans, which allowed implan-
tation of noncross-linked human matrix-containing grafts
without immunosuppression. Adult male baboons (Papio
Anubis, 20–30 kg) are physically large enough to support
implantation of a 6 mm inner diameter TEVG in a clinically
relevant anatomic setting.
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Thesurgicalportionofthisstudyhasbeendescribedelsewhere
for TEVGs [16]. Briefly, nine adult male baboons underwent
arteriovenous placement of human TEVGs (6 mm inner
diameter). One TEVG was placed between the aorta and the
vena cava for 1 month. Eight TEVGs were placed for up to
6 months between the axillary artery and distal brachial vein
in the upper arms of baboons, which provided a superficial
site amenable for simulating hemodialysis access at 1, 3, and
6m o n t h s[ 16]. Arteriovenous PTFE grafts were also placed
in the baboon model between the aorta and vena cava (one
graft for 1 month) and between the axillary artery and distal
brachial vein in the upper arm (one graft for 6 months). All
animals received only one graft to minimize risk of heart
failure. All anastomoses were created with a running 6–0
prolene suture technique. One TEVG remained in vivo at the
time of analysis. Two other animals with upper arm TEVGs
were excluded from histological evaluation in this study. In
one animal, technical difficulties with access resulted in
prolonged manual pressure on the TEVG, which led to graft
occlusion, unrelated to intimal hyperplasia. The other animal
was excluded after pulling open its surgical incision site,
exposing the TEVG and creating a wound infection.
Duplex Ultrasound
In the baboon upper arm model, duplex ultrasound was
used to monitor diameter (D) and maximum velocity (Vmax)
preoperatively for native vessels, postoperatively for the
graft, and then again at 2, 4, 12, and 24 weeks for patent
grafts. Flow rates in the aorta-cava model were not
measured since grafts were not accessible to ultrasound.
Flow rate (Q) was calculated as
Q ¼ Vmax=2 ðÞ p ðÞD=2 ðÞ
2 ð1Þ
Histology
Tissues were fixed in 10% neutral buffered formalin,
embedded in paraffin, sliced (5-μm sections), and stained
with hematoxylin and eosin (H&E) or Movat’s. Immunos-
taining was performed for α-smooth muscle actin (SMC
and myofibroblast marker; Dako M0851, 1:400 dilution),
CD31 (endothelial cell marker; Dako M0823, 1:700
dilution), and CD68 (macrophage marker; Thermo
MS397-P1, 1:400 dilution), using 3,3′-diaminobenzidine
stain. All were counterstained with hematoxylin.
Morphometric Analysis of Intimal Hyperplasia
V enous anastomotic sections and juxta-anastomotic sections
of the outflow vein were analyzed for formation of intimal
hyperplasia. Figure 1 demonstrates sectioning of upper arm
grafts. Aorta-cava grafts were sectioned in similar fashion.
Images were taken using an Olympus BX41 microscope
with a mounted Olympus DP25 camera. CellSens standard
imaging software was used for morphometric analysis.
Sections stained with Movat’s were used for analysis
because the presence of elastin in the medial layer of the
vein allowed for clear identification of the intima. The
internal elastic lamina was used to define the transition
between the media and the intima. First, the area of intimal
hyperplasia (AI) was measured in veins at the anastomotic
sites and in juxta-anastomotic outflow vein sections.
Second, the underlying length of vein was measured,
which, before intimal thickening, was the lumen length
(LL). Intimal thicknesses (IT) were calculated as the total
area of intimal hyperplasia divided by the length of the
underlying tissue (IT=AI/LL) [20]. The thickness of the
medial layer was measured in similar fashion, using the
medial area (MA) and the underlying length, which was the
length of the interface (LI) between the medial layer and the
adventitial layer. Medial thickness (MT) was then calculated
as MT=MA/LI. The ratio of intimal thickness to medial
thickness was then IT/MT [21]. The ratio of intimal area to
medial area was AI/MA.
Statistical Analysis
Statistical analyses were performed with a Student’s two-
sample t test, assuming unequal variances. Correlations
were assessed using the Pearson method. Two-sided P<
0.05 indicated statistical significance. Numeric values are
presented as the mean±standard error of the mean.
Results
Placement of TEVGs as Arteriovenous Grafts in a Baboon
Model Triggers Mild, Nonaggressive Intimal Hyperplasia
Histology demonstrated that arteriovenous TEVGs in a
baboon model had substantially less intimal hyperplasia at
Fig. 1 Schematic of TEVG placement, and locations of histological
sections taken for assessment of intimal hyperplasia in the brachial vein
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Minimal intimal hyperplasia was observed at the venous
anastomosis with all TEVGs in the baboon model (repre-
sentative image shown in Fig. 2a). The extent of intimal
hyperplasia shown in Fig. 2a for TEVGs is substantially
less than that typically shown in the literature for clinical
PTFE grafts (Fig. 2b). Representative high magnification
images show venous intimal hyperplasia after 6 months in a
baboon model for both TEVGs (Fig. 2c) and PTFE grafts
(Fig. 2d). Notably less intimal hyperplasia was observed
with TEVGs.
Quantification of intimal hyperplasia further demonstrated
that TEVGs were associated with less aggressive intimal
hyperplasia than PTFE grafts in the baboon model (Table 1).
Intimal and medial areas of the vein were quantified (1) at
the venous anastomosis and (2) in the outflow vein proximal
to the anastomosis, for both TEVGs (6 mm diameter) and
PTFE grafts (6 mm diameter) in the baboon model. A ratio
of intimal to medial area was presented to allow bench-
marking to literature reports of PTFE grafts (5 mm diameter)
in a porcine arteriovenous (carotid artery to jugular vein)
model [11]( T a b l e1). In the baboon model, we observed that
intimal hyperplasia formed most readily at the venous
anastomosis and dissipated rapidly along the outflow vein
for PTFE grafts. Thus, in the baboon model, we noted
substantial differences in intimal hyperplasia between
TEVGs and PTFE grafts at the venous anastomosis, but
not in the outflow vein. In the porcine model, quantification
of intimal hyperplasia with PTFE grafts clearly demonstrates
aggressive intimal hyperplasia at only 8 weeks at both the
venous anastomosis and the juxta-anastomotic outflow vein
[11]( T a b l e1). Thus, quantitative analysis and histological
observations suggest that TEVGs may prompt less intimal
hyperplasia than PTFE grafts, especially at anastomotic
sections at the graft/vein interface.
Cell populations in venous intimal hyperplasia in
anastomotic sections were determined via immunostaining
(Fig. 3). Actin-positive cells were identified throughout the
intimal tissue (Fig. 3a). Actin-positive cells are typically
observed in intimal hyperplasia associated with arteriove-
nous fistulae or arteriovenous PTFE grafts [14].
CD-31-positive cells (endothelial cells) were observed
on the luminal surface, but were not observed within the
intimal tissue (Fig. 3b). Others have shown microvessel
formation within venous intima that is defined by positive
staining for endothelial cell markers [10]. Furthermore,
microvessel formation indicates an aggressive type of
intimal hyperplasia [22]. Thus, the absence of microvessel
Fig. 2 V enous intimal hyperpla-
sia is minimal at 3 months for
TEVGs in a baboon model. a
V enous anastomosis of a TEVG
explanted at 3 months (G and V
denote the graft and vein,
respectively). b V enous anasto-
mosis of a PTFE graft explanted
from a human (PTFE image
courtesy of Dr. Prabir Roy-
Chaudhury, modified and
reprinted with permission from
Kelly et al. [22]). High magni-
fication of the shoulder region
of the venous anastomosis of c a
TEVG at 6 months in the
baboon model and d a PTFE
graft at 6 months in the baboon
model. Arrows in c and d indi-
cate the interface between the
media and intima, with the
intima positioned below the
media
Table 1 Ratio of intimal area to medial area
Arteriovenous
access creation
method
Ratio of intimal area to
medial area at venous
anastomosis
Ratio of intimal
area to medial area
in outflow vein
TEVGs in a baboon
model
0.37±0.10 0.18±0.10
PTFE grafts in a
baboon model
1.3±0.6 0.11±0.01
PTFE grafts in a
porcine model
a
0.87 0.33
aFrom Rotmans et al. [11]
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TEVGs prompt a nonaggressive form of intimal hyperplasia.
CD-68-positive cells (macrophages) were very sparse
(Fig. 3c). In contrast, a substantial macrophage population
has been observed within intimal tissue adjacent to PTFE
arteriovenous grafts [10]. The prominent macrophage
population that infiltrates PTFE grafts releases cytokines
and growth factors and thereby promotes intimal hyperpla-
sia [14, 23, 24]. Thus, the inflammatory characteristic of
synthetic PTFE is thought to increase the aggressiveness of
intimal hyperplasia. TEVGs likely have substantially less
macrophage-related stimulation of intimal hyperplasia than
PTFE.
The extent of intimal hyperplasia formation was not
significantly different between 3 and 6 month explants
(Table 2, P=0.3). Although this nonaggressive intimal
hyperplasia did not appear to worsen with time, we
observed variation in the extent of intimal hyperplasia
between grafts (note high values for standard error of the
mean). In contrast, other groups have demonstrated that
PTFE grafts trigger intimal hyperplasia that grows substan-
tially with time [11, 25]. The observation that intimal
hyperplasia did not worsen significantly between 3 and
6 months led us to study variability between TEVG
recipients, as variability is always observed in the clinic
and in animal models.
The Mild Intimal Hyperplasia that Forms with Arteriovenous
TEVG Placement is Influenced by Host Blood Flow Rate
and V enous Adaptation to Flow Rate
The goal of placing arteriovenous grafts for hemodialysis
access is to increase blood flow above 300 ml/min to allow
for successful hemodialysis [26]. Implantation of arteriove-
nous grafts allows blood to flow from the artery to the vein
with diminished resistance. The new path of decreased
resistance, from the artery to vein via the graft, minimizes
the impact of back pressure from tapering distal arteries on
arterial flow rate and thereby allows flow to increase.
As anticipated, placement of TEVGs as arteriovenous
grafts in the baboon upper arm model increased flow rates
(Fig. 4a). Preoperative flow rates for the inflow artery and
outflow vein were 301±85 and 68±13 ml/min, respectively. Fig. 3 Immunostaining of venous intimal hyperplasia that is
associated with arteriovenous TEVGs. Large arrows indicate the
interface between the media and intima, with the intima positioned
below the media in all panels. a Alpha-smooth muscle actin positive
cells (stain brown) are observed in the media and in the intima. b
CD31-positive cells (positive cells stain brown; blue nuclear counter-
stain) were observed on the luminal surface but not within the intima.
c CD68-positive cells (positive cells stain brown; blue nuclear
counterstain) were sparse (small arrow points to the only cell that
stains positively for CD68 in this field of view, located in the media of
the vein). Representative 6-month images are shown
Table 2 Intimal hyperplasia at 3 and 6 month explants
Ratio of intimal area to
medial area at venous
anastomosis
Ratio of intimal area
to medial area in
outflow vein
TEVGs explanted at
3 months
0.57±0.35 0.38±0.38
TEVGs explanted at
6 months
0.30±0.03 0.11±0.05
678 J. of Cardiovasc. Trans. Res. (2011) 4:674–682Mid-graft flow reached 709±195 ml/min immediately
after implant. Flow rates through TEVGs increased
further by week 2 (P=0.009, Fig. 4a), with a range of
1,081–3,127 ml/min at 2 weeks. Mid-graft flow through
the PTFE graft in the baboon upper arm model was
963 ml/min at 2 weeks. Mid-graft flow through TEVGs
displayed a decreasing trend between weeks 2 and 4 (P=
0.06) and reached a steady-state level of flow thereafter
(Fig. 4a; no significant differences were detected between
flow rates at 4, 12, and 24 weeks, P>0.2).
Intimal hyperplasia has been shown to be triggered by
high wall shear stresses that accompany high flow rates
[15]. Others have observed that flow rates decrease as
intimal hyperplasia progresses [11]. Therefore, we con-
sidered the hypothesis that (1) the high week 2 flow rates
trigger intimal hyperplasia and (2) the absence of a
decrease in flow rate after week 4 may indicate that
intimal thickening occurred primarily within the first
4 weeks of implant.
At week 2, TEVG mid-graft flow rates positively
correlated with the extent of intimal hyperplasia formation
in the vein (Fig. 4b). Specifically, higher flow rates at week
2 were associated with an increase in the ratio of intimal
thickness to medial thickness in the vein at explant, both in
anastomotic and in juxta-anastomotic sections (P=0.04 for
correlation between flow rate at week 2 and venous
anastomosis thickness ratio, and P=0.02 for correlation
between flow rate and juxta-anastomotic outflow vein
thickness ratio). Our findings for TEVGs are in agreement
with a clinical study, which demonstrated that week 2
velocity was correlated with the extent of venous intimal
hyperplasia formation triggered by arteriovenous PTFE
grafts [27].
No significant correlations were observed between
intimal thickening and flow rate through TEVGs at any
time points other than week 2 (P>0.3 for weeks 0, 4, 12,
and 24). The lack of a correlation between flow rate and
intimal hyperplasia beyond week 4 suggests that much of
the intimal thickening may have occurred largely within the
first 4 weeks of implant. Time-course assessments of
intimal hyperplasia with PTFE grafts in a porcine model
have shown substantial intimal growth in histological
sections by week 2 and another increase in intimal growth
between weeks 2 and 4 [11], which supports the ability of
intimal hyperplasia to form in this early time frame.
Evaluation of outflow vein diameter further supports our
hypothesis that intimal thickening occurs largely within the
first month of implant and then reaches a plateau. We
observed outflow vein dilatation within 2 weeks of TEVG
placement (Fig. 5, P=0.0007). Outflow vein diameter
decreased between weeks 2 and 4 (P=0.03) and reached a
steady-state level thereafter (no significant differences
between weeks 4, 12, and 24, P>0.4).
Given that outflow vein dilatation is thought to be
prompted by the increase in shear stress that accompanies
an increase in flow rate [28] and that veins dilate in an
attempt to return shear stress levels back to normal [29], it
is logical that our diameter observations match the temporal
trend presented for flow rate in Fig. 4a. This agrees with
one of the few clinical studies that has tracked flow and
dilatation using ultrasound, wherein increases in flow rate
led to venous dilatation in fistulas [30].
The observed decrease in diameter between weeks 2 and
4 (Fig. 5) likely correlates with a period of active intimal
thickening. Given that diameter did not decrease after week
Fig. 4 Flow rates. a Flow before and after placement of TEVGs as
arteriovenous grafts (Pre-op preoperative, Wk week). Superscript
letter a modified and reprinted with permission from Dahl et al.
[16]. b Flow rate at week 2 impacted the extent of intimal growth
Fig. 5 Outflow vein diameters changed after placement of TEVGs as
arteriovenous grafts
J. of Cardiovasc. Trans. Res. (2011) 4:674–682 6794, we submit that venous intimal thickening occurred mostly
within 4 weeks of TEVG implant. Note that there was no
statistical correlation between preoperative vein diameter and
intimal hyperplasia formation, which suggests that flow-rate-
mediated remodeling, and not preoperative anatomy, dictated
intimal hyperplasia formation.
Discussion
TEVGs have compliances within the range of human artery and
vein and have been shown to be noninflammatory in vivo [16].
In this study, we demonstrate that the venous intimal
hyperplasia that forms in response to arteriovenous placement
of TEVGs in a baboon model is only a mild type of intimal
hyperplasia, as indicated by less intimal hyperplasia formation
than observed with PTFE grafts, the absence of intimal
microvessel formation, and a very sparse macrophage popula-
tion. Furthermore, this mild intimal hyperplasia did not
progress between 3 and 6 months. For TEVGs, we conclude
that the extent of venous intimal tissue formation was likely
driven by early changes in flow rate. High flow rates may be
associatedwithhighshearstress,turbulentflow,flow separation,
and oscillatory shear. Additionally, we suggest that the intimal
hyperplasia associated with TEVGs largely forms within the
first month of implant and does not grow aggressivelythereafter.
In contrast, PTFE grafts have been shown to be proin-
flammatory and thereby become infiltrated with macrophages
[14, 23]. The intimal hyperplasia that forms with placement of
PTFE arteriovenous grafts is aggressive, as demonstrated by
microvessel formation and continued growth with time [10,
11, 22]. This ongoing growth is likely related to PTFE’s
proinflammatory nature, with a large macrophage population
that continuously triggers intimal hyperplasia [14, 23, 24]. It is
important to note that early PTFE flow rates in the baboon
upper arm model and mean PTFE flow rates in the porcine
neck model (1,065±469 ml/min at 4 weeks [11]) were close to
the lowest flow rates observed in TEVGs. Thus, the
observation that PTFE grafts triggered more aggressive intimal
hyperplasia than TEVGs was likely due to PTFE’si n f l a m m a -
tory nature. The compliance of PTFE (1.6% per 100 mmHg
[31]) is only half that of TEVGs (3.3% per 100 mmHg [16]),
and therefore, compliance mismatch may also be a contributor
toward increased intimal hyperplasia with PTFE grafts.
Mechanisms for venous intimal hyperplasia formation with
TEVGs and PTFE grafts are proposed in Fig. 6.
In addition to posing a problem for arteriovenous grafts,
intimal and medial hyperplasia is also a significant problem
in arteriovenous fistulas [21]. Some triggers for formation
of intimal hyperplasia in arteriovenous fistulas differ from
those in PTFE grafts. Unlike PTFE grafts, fistulas do not
have a large macrophage population to stimulate intimal
formation. However, venous intimal thickening with fistu-
las has been shown to be stimulated in part by expression of
growth factors within the artery [32].
TEVGs are acellular at implant, and the absence of cells
may aid in resistance to intimal hyperplasia. While we have
not performed any analysis for presence or absence of
growth factors in human TEVGs, it is possible that acellular
TEVGs present less growth factor expression than a native
artery, thereby making the outflow vein less susceptible to
intimal hyperplasia. Furthermore, the absence of cells at
early time points makes acellular TEVGs reasonably inert
during the early implant phase, where dynamic changes in
flow are prevalent. ATEVG containing cells might respond
to high shear stresses via cellular proliferation, forming
intimal tissue within the first month of implant when flow
rates and shear stresses are at their highest. The absence of
cells in TEVGs at the time of implant may thereby aid its
ability to resist early cell-mediated intimal injury.
The impact of host blood flow rate on intimal hyperpla-
sia in the vein suggests that future TEVGs (and PTFE
grafts) might better control venous intimal hyperplasia if
the grafts have a mechanism to limit flow rate at the graft
exits. Such a design might prevent exposure of excessive
flow rates to the venous anastomosis and may thereby
reduce the vein’s intimal thickening response. Tapered
PTFE grafts have been evaluated to restrict flow, with the
goal of reducing steal, but have not demonstrated definitive
functional improvements in the clinic [33]. Thus, an
alternate approach to coarctation of the graft likely will be
necessary to confirm the hypothesis that high flow rates
lead to more intimal hyperplasia and address the flow-
related mechanism of intimal hyperplasia formation.
Several animal studies in other labs have focused on
controlling flow rate or shear stress to determine their impact
on intimal hyperplasia formation, yet these studies have been
performed primarily in the arterial circulation or the venous
circulation, but not in arteriovenous models. In the arterial
circulation, increasing blood flow across preformed intimal
tissue led to regression of the intima in a baboon model [34]. In
Fig. 6 Proposed mechanisms for outflow vein intimal hyperplasia
formation with arteriovenous placement of TEVGs and PTFE grafts
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to promote intimal hyperplasia in a rabbit model [35].
Substantial differences in hemodynamics exist between bypass
and arteriovenous grafts [15], and therefore, it is difficult to
extrapolate these findings to the arteriovenous setting.
The study described herein has several known limita-
tions. First, this is an early study with a small number of
subjects. The trends observed are sensible, but we plan to
continuously monitor these trends in future animals as more
data on arteriovenous TEVG implantation is acquired.
Second, animals were treated with aspirin throughout the
course of this study, which has been shown to decrease
intimal hyperplasia [36]. However, aspirin therapy is
recommended clinically [37] and is used routinely in
preclinical models that study intimal hyperplasia, including
those referenced as benchmarks in this study [11, 22, 25].
The baboon model had clear benefits for evaluation of a
human vasculargraft. Baboons are old world primates, which
are phylogenetically closer to humans than more common
cardiovascular large animal models, such as pigs, dogs, and
sheep. The concordant baboon model abrogated risk of
xenogenic immune response to a human cardiovascular
implant. Furthermore, the vascular anatomy of baboons was
largeenoughtosupportimplantationofa6mmdiametergraft.
In addition, the clotting and fibrinolytic systems of primates
are more closely related to humans [38]. Therefore, baboons
served as the best model for human-based cardiovascular
implants. In contrast, PTFE grafts are frequently evaluated in
animal models that are affordable and widely available
(e.g., pigs) because PTFE is not at risk of triggering a
xenogenic immune response.
The baboon model, however, also had clear limitations.
Primates are significantly more expensive to purchase and
maintainthananyotheranimal[39], are difficult to handle and
maintain [40], and are limited in availability. In order to
circumvent the issues of high costs and limited animal
availability, we considered implanting a PTFE graft in the
contralateral arm of each animal. After careful consideration,
we did not pursue this strategy because implantation of two
high-flow arteriovenous grafts in each animal would lead to a
substantial increase in cardiac output, which would create a
real risk of heart failure. These limitations constrained our
ability to evaluate a large number of PTFE control grafts, so
only two control grafts were implanted. Therefore, in addition
to presenting data on these two control PTFE grafts in the
baboon model, we have presented data from literature reports
of arteriovenous PTFE grafts in porcine animal models.
Conclusions
The results of this study provide a useful framework with
which we can think about intimal hyperplasia formation.
The correlation between early flow rates and intimal
formation may also translate to venous intima development
with fistulas and PTFE grafts. Only a handful of studies
have histologically analyzed intimal hyperplasia in fistulas
and PTFE grafts, yet these studies are primarily focused on
failed arteriovenous grafts or fistulas [10, 21, 23] since
functioning access sites are not explanted. Furthermore,
failed access sites are rarely removed. Thus, the insights
provided by this study can contribute the body of
knowledge regarding progression of intimal hyperplasia
and its triggers.
Use of TEVGs in a baboon arteriovenous model led to
mild, nonaggressive intimal hyperplasia that likely formed
within 1 month of implant. TEVGs are noninflammatory and
compliant, and thereby avoid two common triggers of
arteriovenous PTFE grafts for progression of intimal hyper-
plasia. Histological assessments demonstrated that TEVGs
had less intimal hyperplasia than PTFE grafts. TEVGs that
resist substantial intimal hyperplasia could possibly provide a
new treatment optionfor patientswithendstage renal disease.
Both reduced incidence of intimal hyperplasia failure and
slowed progression of intimal hyperplasia-related failure
could lead to a decrease in surgical intervention of arteriove-
nous access grafts. Decreased surgical intervention, in turn,
could decreaseoverall endstage renal disease healthcarecosts
and patient morbidity.
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